Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GIA632 · 2 trials · 2 indications
The F-VASI assesses the percentage of facial area affected by vitiligo. It ranges from 0 to 3.5, with 0 representing no vitiligo on the face and 3.5 representing complete depigmentation of the assessed facial areas.
To assess the efficacy of GIA632 compared to placebo at week 16
| Arm | Type | Description |
|---|---|---|
| GIA632 Arm 1 | EXPERIMENTAL | GIA632 will be administered during the 48-week core period. |
| GIA632 Arm 2 | EXPERIMENTAL | GIA632 will be administered during the 48-week core period. |
| GIA632 Arm 3 | EXPERIMENTAL | GIA632 will be administered during the 48-week core period. |
| GIA632 Arm 4 | EXPERIMENTAL | GIA632 will be administered during the 48-week core period. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered during the 48-week core period. |
| GIA632 | EXPERIMENTAL | Active treatment arm |
| Name | Type | Description |
|---|---|---|
| GIA632 | DRUG | GIA632 will be administered during the 48-week core period. |
| Placebo | DRUG | Placebo will be administered during the 48-week core period. |
Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study * Male or female as assigned at birth ≥ 18 years of age at the time of screening * Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by ...
Top 20 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Baricitinib, corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | 611, corticosteroid |
| Co-Diagnostics, Inc. | CODX | 1 | PHASE3 | 611 |